N- (6- methoxy- 5- (2- methoxyphenoxy)- 2- (pyrimidin- 2- yl)pyrimidin- 4- yl)- 2- phenylethenesulfonamide (YM598)

06/01/2005 - "YM598 also improved the hypoxemia which was induced by 3 weeks of exposure to hypoxia. "
11/01/2004 - "YM598 also improved hypoxemia and morphological pulmonary lesions in these rats. "
06/01/2005 - "These results suggest that repeated oral administration of YM598 to rats with chronic hypoxia effectively prevented the development of PH. Oral administration of YM598 also improved hypoxemia in this model. "
06/01/2005 - "Oral administration of YM598 at a dose of 1 mg/kg was started on the first day of chronic hypoxia exposure for 2 and 3 weeks to investigate the effects of this compound on hemodynamic and arterial blood gas variables, respectively. "
08/02/2004 - "YM598 also improved hypoxemia which accompanied with the severe pulmonary hypertension in these rats."

06/01/2005 - "These data strongly suggest that YM598 will be clinically useful in the treatment of patients with either primary or secondary pulmonary hypertension."
08/02/2004 - "YM598 also improved hypoxemia which accompanied with the severe pulmonary hypertension in these rats."
08/02/2004 - "In the therapeutic study, YM598 also ameliorated the pulmonary hypertension and hypoxemia in monocrotaline-treated rats. "
06/01/2005 - "The preventive effects of the novel and selective endothelin ET(A) receptor antagonist YM598 on the development of pulmonary hypertension (PH) were investigated in chronic hypoxia-induced PH rats. "
06/01/2005 - "A novel and selective endothelin ET(A) receptor antagonist YM598 prevents the development of chronic hypoxia-induced pulmonary hypertension in rats."

06/01/2005 - "Repeated oral administration of YM598 significantly suppressed the increase in pulmonary arterial pressure, right ventricular hypertrophy, and pulmonary and systemic congestion. "
08/02/2004 - "YM598 suppressed the increase in pulmonary arterial pressure, right ventricular hypertrophy and systemic congestion, and improved the hypoxemia, but bosentan had only modest effects. "
11/01/2004 - "In right-side heart failure rats, oral YM598 (0.1 and 1 mg/kg for 4 weeks), but not bosentan (30 mg/kg), significantly inhibited the progression of pulmonary hypertension and the development of right ventricular hypertrophy. "

11/01/2004 - "YM598 prolonged running time, which had been shortened as a result of heart failure. "
11/01/2004 - "These findings suggest that YM598 may have a clinical benefit with regards to ameliorating the cardiopulmonary changes of right-side heart failure, and the cardiac dysfunction and mortality/morbidity of CHF."
11/01/2004 - "The effects of long-term administration of YM598, a selective endothelin-A antagonist, on improving the exercise tolerance of chronic heart failure model rats were examined using a treadmill exercise loading test. "
11/01/2004 - "The effects of the novel, selective endothelin-A (ETA) receptor antagonist YM598 on both-side heart failure were investigated. "
11/01/2004 - "YM598, an orally active ET(A) receptor antagonist, ameliorates the progression of cardiopulmonary changes and both-side heart failure in rats with cor pulmonale and myocardial infarction."

01/01/2007 - "These data suggest that YM598 has potential as a novel therapeutic agent for inhibiting liver metastasis of gastric cancer."
01/01/2007 - "The ET-A blockade by YM598 had a strong inhibitory effect against tumor growth and liver metastasis of the gastric cancer cell lines. "
01/01/2007 - "To investigate the role that ET-A plays in gastric cancer metastasis, we studied the effect of an ET-A-selective antagonist, YM598, on cell proliferation, tumor growth, and liver metastasis of the highly liver metastatic cell line AZ-H5c, established from the low metastatic human gastric cancer cell line AZ-521. "